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creativecommons.org/licenses/by-nc-nd/Abstract Background: Organised cervical cancer (CC) screening programmes are delivered
in many different ways across the European Union and its regions. Our aim was to systemat-
ically review the impact of these programs on CC mortality.
Methods: Two independent reviewers identified all eligible studies investigating the effect of
organised screening on CC mortality in Europe. Six databases including Embase, Medline
and Web of Science were searched (March 2018) with predefined inclusion and exclusion
criteria. Only original studies with at least five years of follow-up were considered. Validated
tools were used to assess the risk of bias of the included studies.
Results: Ten observational studies were included: seven cohort and three case-control studies.
No randomised controlled trials were found, and there were no eligible studies from the
eastern and southern part of Europe. Among the eligible studies, seven were conducted in
the twentieth century; they scored lower on the risk of bias assessment. CC mortality reduction
for women attending organised screening vs. non-attenders ranged from 41% to 92% in seven
studies. Reductions were similar in Western (45e92%) and Northern (41e87%) Europe andf Public Health, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, Rotterdam,
smc.nl (E.E.L. Jansen).
"EU-TOPIA consortium" are listed in appendix section.
blished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
4.0/).
E.E.L. Jansen et al. / European Journal of Cancer 127 (2020) 207e223208were higher in the three more recent studies (66e92%). For invited vs. non-invited women, this
reduction ranged from 17% to 79% in five studies.
Conclusion: Although data were lacking in Southern and Eastern Europe and the effect size
varied between countries and studies, this systematic review provides evidence that organised
CC screening reduces CC mortality in those parts of Europe where CC screening was imple-
mented and monitored.
ª 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cervical screening has been shown to reduce the incidence
and mortality of cervical cancer (CC). Precancerous le-
sions can be treated, preventing progression to invasive
disease [1e6], thereby avoiding the need for chemo-
therapy or radiotherapy or infertility due to removal of
the cervix [7e9]. Screening is estimated to reduce the
incidence rate of CC by 50e60% [10]. Yet although most
European countries have offered some sort of CC
screening for decades [11], 34,000 new CC cases are
detected in Europe each year, with 13,000 deaths [12].
CC screening is most effective where it is undertaken
within an organised programme. Yet, so far, 19 of the 28
countries of the European Union have yet to implement
such programmes despite clear recommendations agreed
by the European Council [13e15]. These recommenda-
tions advocate starting screening at an age between 20
and 30, repeating at three to five year intervals until the
age of 60 or 65 [16,17]. Screening can be performed
using a Pap smear to detect any abnormal cells
(cytology) and/or a test to check for the presence of the
human papilloma virus (HPV), the causal agent in CC
[17,18]. While ten countries are currently rolling out an
organised CC screening programme and three countries
are currently planning or piloting such programme, six
countries only have a non-populationebased pro-
gramme or no programme at all [13,14].
The reduction in mortality that can be achieved by a
screening programme depends on several factors. These
include the epidemiology of HPV infection in the pop-
ulation and characteristics of the screening programme,
including the starting and stopping ages, screening in-
terval and coverage [19]. Other factors include the per-
formance of screening activities, in terms of sensitivity
and specificity, access to treatment by those in whom
lesions are detected and quality of follow-up. These
parameters can vary widely so it is likely that observed
reductions in CC mortality will also vary. However, the
extent to which screening does achieve reductions in
Europe, including differences among countries and over
time, has not previously been brought together
systematically.
This systematic review is part of the EU-TOPIA
(TOwards imProved screening for breast, cervical and
colorectal cancer In All of Europe) project that is eval-
uating and quantifying the harms and benefits of cancerscreening in European countries, to improve health
outcomes and increase equity. Both women and poli-
cymakers should know whether their screening pro-
grammes are performing optimally and the scale of the
benefit that they can expect. This review seeks to address
this question by searching for the best quality published
evidence on the effect of screening on reducing CC
mortality in the European region. This can be used to
benchmark progress in countries with existing screening
programmes and those that are starting new ones.
2. Methods
The systematic review was part of a large one on cancer
mortality reduction associated with screening for breast,
colorectal and CC within the EU-TOPIA project. The
protocol of this systematic review was published in
PROSPERO (International Prospective Register of Sys-
tematic Reviews, CRD42016042433) on July 6, 2016 [20].
ThePreferredReporting Items for SystematicReviews and
Meta-Analyses (PRISMA) statement served as a guideline
for the performance of this systematic review [21].
2.1. Search strategy
The PICOS (population, intervention, control, outcome
and study design) criteria (Table 1) from the study
protocol [20] formed the basis of the search strategy in
six electronic databases. Embase, Ovid Medline, Web of
Science, PubMed, Google Scholar and the Cochrane
Library were searched from inception until March 2018
for articles in English related to population-based CC
screening and effects on CC mortality in European
countries using a computer-assisted search code
compiled by a research librarian (appendix Table A).
Experts from the field were invited to suggest additional
relevant articles and grey literature to be added to the
list of potentially eligible articles. We also manually
searched reference lists of pertinent articles to find any
relevant citations that our searches might have missed.
Duplicates were removed, and the remaining references
were managed using Thomson Reuters Endnote X7.5.
2.2. Study selection
All retrieved references were screened for title and ab-
stract by two investigators (E.J. and N.Z.)
Table 1
PICOS criteria used to include/exclude studies during the study selection process.
Parameter Inclusion criteria Exclusion criteria
Population People invited to/participating in organised mass screening
for cervical cancer in a European country.
People from non-European countries.
Intervention Organised screening for cervical cancer. Other screening interventions (e.g. opportunistic screening).
Control People not invited to/not attending organised screening or
people participating in opportunistic screening only.
Control group receiving a different type of screening (e.g.
comparing cytology with HPV screening).
Outcome Change in cervical cancer mortality due to cervical cancer
screening.
No direct estimation of cervical cancer mortality reduction
due to screening.
Study design Randomised control trials, retrospective and prospective
observational (cohort or case-control) studies.
Non-original research studies (e.g. editorials, letters and
conference abstracts), modeling/simulation studies,
ecological studies, systematic reviews and meta-analyses.
Follow-up < 5 years.
PICOS, population, intervention, control, outcome and study design; HPV, human papilloma virus.
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based on the eligibility criteria listed in Table 1.
Following the IARC Handbook of Cancer Prevention
[22], we defined organised screening as that within a
programme organised at national or regional level based
on an explicit policy. Where only incidence reduction
was reported in the abstract, the article was included for
full-text review to ascertain whether CC mortality
reduction was reported elsewhere in the article. Dis-
crepancies were resolved by consensus or by consulting a
third investigator (A.G.) for a final judgement.
Initially, included articles were subjected to a full-text
review using additional exclusion criteria inspired by
Elmunzer et al. [23] Briefly, articles were excluded if (1)
the study did not assess the direct effect of organised CC
screening on CC mortality, (2) the study assessed test
performance rather than the effect at population level,
(3) the study did not present original data (information
was duplicated in other articles), (4) the follow-up
period was less than five years, (5) the study neither
reported the number of events (in both intervention and
control groups where appropriate) nor presented an
outcome measure based on the relative risk (RR), rate
ratio, odds ratio (OR) or percentage reduction.
2.3. Data extraction and risk of bias assessment
Data were extracted from the final list of included
studies on first author, year of publication, country of
the study, study design, organisation of screening
implementation (regional or national), study group
sizes, whether the control group was drawn from the
same population as the intervention group, number of
events, adherence to the intervention, follow-up time,
target ages of the intervention, screening interval, all
outcome measures regarding CC mortality reduction
including reported 95% confidence intervals (CIs) and a
note if this outcome measure was corrected for self-
selection bias (healthy individuals are more likely to
attend screening). The presence of conflict of interest
statements and/or funding source from all included
studies was also extracted. All relevant outcomemeasures are presented in a table, sorted by European
region as defined by the EuroVoc multilingual thesaurus
of the European Union [24].
When comparing reductions in CC mortality across
studies, odds ratios were interpreted as being RRs as
these will be very similar as long as the incidence of the
event is less than 10% in the overall population [25]. This
also applies to case-control studies [26].
To assess the risk of bias of included studies, two
investigators independently scored the risk of bias using
the Newcastle-Ottawa Scale (NOS) for observational
studies, covering the domains of study group selection,
comparability between the study groups, outcome
measurement and exposure to the intervention [27].
Because of the differences in the study design between
cohort studies and case-control studies, different types
of biases could occur so the NOS applies different
questions to each [27]. A higher score on the NOS cor-
responds to less risk of bias. The NOS initially did not
award a point for adequate case definition of case-
control studies if this was based on record linkage
only. Anttila et al. [28] advocated that cancer registries,
when mandated and resourced, should take co-
responsibility in the evaluation of the quality and
impact of organised screening. In addition, as cancer
registries in some countries have a very high percentage
of histologically verified cases, which we designated as
independent validation, we did award a point for this if
the percentage was known to be more than 95% ac-
cording to the International Agency for Research on
Cancer [29]. All scoring discrepancies between reviewers
were discussed until consensus was reached. Final de-
cisions about remaining discrepancies were made by the
third investigator. Studies were sorted by NOS score in
the result tables providing the opportunity for readers to
interpret the results accordingly.
3. Results
The number of references remaining at each step of
the study selection process is shown in the PRISMA
flow chart in Fig. 1. The initial search of the six
Fig. 1. Flow chart for article search and selection process.
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field added 61 references, while the reference lists iden-
tified a further 15 studies to be screened, adding up to 76
extra references. After removing duplicates, 1816 studies
remained for title/abstract screening. The two indepen-
dent reviewers reached consensus to include 66 articles
that potentially fitted the predefined PICOS criteria for
full-text review. Two studies were excluded because the
full-text articles appeared to be unavailable in English.
Of the remaining 64 articles, 54 were excluded for a
variety of other reasons (Fig. 1). Ultimately, this review
included a total of ten studies. All included studies were
present in the initial database search. Excluded articles
are listed in appendix Table B including reasons for
exclusion.
3.1. Characteristics of the included studies
All included studies were observational, and no rando-
mised controlled trials (RCTs) were found. Of the ten
studies included, seven were performed in Northern
European countries and three were in Western Euro-
pean countries (Table 2). Three case-control studies
were included, whereas the other references were allfrom cohort studies. The case-control studies included
108, 198 and 110,619 cases, whereas the control groups
comprised 216, 1218 and w23,000 subjects, respectively
[30e32]. The sample sizes in the cohort studies varied
from 15,257 to about 4,200,000 women, although not all
reported the exact sample size. Across studies, the
starting age for screening was between 20 and 35 while
screening was performed until age 49 to 69 with intervals
ranging between two and five years. One study [31] did
not report the screening interval. The follow-up time
was at least five years in the cohort studies [33], with a
maximum of 36 years [34]. Adherence in the cohort
studies ranged from 72% to 86%, although this infor-
mation was missing from three studies [33e35]. The year
in which the studies were published ranged from 1979 to
2016 with most published before 1995.
3.2. Risk of bias
The risk of bias varied between studies (Table 2).
Three studies [31,33,36] scored four of nine points on the
NOS, four studies scored five or six points and three
studies [30,32,37] scored seven, eight or nine points. Two
of three studies from Western Europe were among those
Table 2
Characteristics, risk of bias and results on cervical cancer mortality of included studies, by region (based on EuroVoc) and quality score.
Region/Study Country Study
type
Participants Target age
(years)
Screening
interval
(years)
Follow-up
(years)
Adherence
(%)
Correction for
self-selection
bias
NOS
scorea
RR (95% CI) for
cervical cancer
mortality (invited)
RR (95% CI) for cervical
cancer mortality
(participated)
Northern Europe [24]
Lo¨nnberg S, 2013 [30] Finland Case
control
198 cases (71b)
1218 controlsc (876b)
25e69 5 N/A N/A Yes 9/9 0.34 (0.14e0.49)
Dugue´ P, 2014 [37] Denmark Cohort 903,439 participants
253,232 non-
participantsc
23e59 3 13 78 No 7/9 0.13 (0.11e0.15)
Bergstro¨m S, 1999 [34] Sweden Cohort 24,389 cases
10,655 deaths
30e49 4 26e36 86d Invited vs.
non-invited
6/9 0.21 (N/A)
Ma¨hlck C, 1994 [35] Sweden Cohort w4.200.000 invited 30e49 4e5 22 86d Invited vs.
non-invited
6/9 0.47 (0.28e77)
Berget A, 1979 [48] Denmark Cohort 13,148 participants
2109 non-participantsc
30e49 4e5 6e8 86 Yes 6/9 0.70 (N/A)e 0.16 (N/A)
Lynge E, 1989 [49] Denmark Cohort N/A 20e59 2 15 72e81 Invited vs.
non-invited
5/9 0.68 (0.59e0.78)
Magnus K, 1987 [36] Norway Cohort 45,960 invited 25e59 2e4 24 76 Yes 4/9 0.83 (N/A) 0.59 (N/A)
Western Europe [24]
Landy R, 2016 [32] United
Kingdom
Case
control
11,619 cases
w 23,000 controlsc
35e64 3e5 5 N/A No 8/9 0.08 (0.07e0.09)
Macgregor E, 1994 [31] Scotland Case
control
108 cases (38b)
216 controlsc (157b)
25e60 N/A N/A N/A No 4/9 0.25 (0.12e0.48)
Ebeling K, 1986 [33] Germany Cohort N/Ac 20e64 2 5 N/A No 4/9 0.09 (N/A)
NOS, Newcastle-Ottawa Scale; CI, confidence interval; N/A, not available; RR, relative risk (odds ratio and percent reduction are presented as a RR because they are similar because of the relative low
incidence of cervical cancer) [25].
Target age: Ages targeted by the organized screening programme; Follow-up: Follow-up time after initiation of the screening programme.
a Quality assessment made according to the Newcastle-Ottawa Scale.
b Exposed to screening.
c Controls were drawn from the same population as the intervention group.
d Estimation based on Stenkvist et al. (1984), women with 2 or more smears over a ten-year period [47].
e Not significant.
E
.E
.L
.
J
a
n
sen
et
a
l.
/
E
u
ro
p
ea
n
J
o
u
rn
a
l
o
f
C
a
n
cer
1
2
7
(
2
0
2
0
)
2
0
7e
2
2
3
2
1
1
E.E.L. Jansen et al. / European Journal of Cancer 127 (2020) 207e223212with four points. The most common criteria that
affected the risk of bias assessment were a lack of in-
formation on the prevalence of CC at the start of the
study and on the length of the follow-up. Furthermore,
authors often failed to correct for any differences be-
tween the intervention and control groups (e.g. age) and
did not specify the method by which the exposure to the
intervention was measured. Tables C.1 and C.2 in the
appendix provide the arguments for each score on the
NOS. An overview of all conflict of interest statements is
provided in appendix Table D.3.3. CC mortality outcomes
All included studies reported a reduction in CC mor-
tality (Table 2) in those attending screening compared
with non-attenders (Fig. 2a) and in those invited for
screening compared with non-invited women (Fig. 2b),
although not all studies reported whether this reduction
was found to be significant or not. In cohort studies
reporting the effect of inviting a population for
screening, the CC mortality reduction was between 17%
and 79% in Northern Europe; no such studies were
performed in other regions. In cohort studies from
Northern Europe, CC mortality reduction among those
participating in screening was between 41% and 84% in
studies that corrected for self-selection bias and 87% in
the study that did not do so. The cohort study from
Western Europe did not correct for self-selection bias
and reported a CC mortality reduction of 91%. In the
case-control study in Northern Europe, the OR of dying
from CC after participating in screening compared with
non-participants, and corrected for self-selection bias,
was 0.34 (95% CI: 0.14e0.49) [30]. In the two case-
control studies from Western Europe, the ORs were
0.08 (95% CI: 0.07e0.09) [32] and 0.25 (95% CI:
0.12e0.48) [31], both uncorrected for self-selection bias.4. Discussion
This systematic review shows that there is relatively little
published evidence on CC mortality reduction after
implementation of organised CC screening in Europe.
No RCTs were reported from Europe, and there were
no studies of any sort from Southern and Eastern
Europe. However, in Northern Europe, two recent high-
quality observational studies were reported. One showed
a 51e86% CC mortality reduction after participation in
organised screening, corrected for self-selection bias [30],
and the other showed a 85e89% CC mortality reduction
without correction for self-selection bias. In the 1990s,
two large cohort studies were performed, showing a
23e72% CC mortality reduction after invitation for
screening, although the target age range in the screening
programmes at that time was still restricted to 30e49
years. In Western Europe, one recent high-quality studywas conducted showing a 92% CC mortality reduction
without correction for self-selection bias. The other two
studies from Western Europe were both conducted
before 1995 and scored four points on the NOS scale.
Overall, therefore, the evidence confirms that screening
for CC is associated with CC mortality reduction.
This conclusion is in line with a previous review
performed by Peirson et al. [38] who found an associa-
tion between screening for CC and CC mortality
reduction. However, Peirson et al. [38] mainly found
incidence reduction studies during their search, while
focussing on a single Indian RCT when assessing CC
mortality reduction (RRZ 0.65 [95% CIZ 0.47, 0.90]).
The conclusions of this trial might not be applicable to
the European setting as the background risk is likely to
be different and the trial assessed the effect of a single
lifetime screening only. To our knowledge, no other
systematic reviews have been performed on the effect of
CC screening on CC mortality.
The main strength of this systematic review is that it
summarises all current existing evidence on the effects of
CC screening on CC mortality in Europe while also
providing information on the risks of bias within those
studies. The scale of the reduction in CC mortality that
we found is an important reason to implement or
improve a CC screening programme. The effect size of
the included studies varied, which can be explained by
various reasons. Differences in CC mortality reduction
between an invited and an attending population will
depend on attendance rates of the invited population.
Within the group of attenders, differences in CC mor-
tality reduction can be expected based on follow-up
time, general background risk, demographics of the
study population and the characteristics of the screening
programme and screening tests [19]. Furthermore, dif-
ferences in effect size can be caused by selection of any
control group if there is no correction applied for any
differences in background risk, and the effect size can
also be influenced by differences in treatment effective-
ness over time and between countries [1]. To quantify
the effects of each of the parameters affecting CC
mortality reduction, simulation models could be used.
These simulation models can mimic the natural history
of CC in a population and apply different screening
scenarios to compare expected CC mortality reduction
between those scenarios. Despite all the different study
settings in the studies found in this systematic review,
there was a clear reduction in CC mortality in all ten
included studies, of which most showed a statistical
significant difference. This provides robust evidence that
organised CC screening is able to reduce CC mortality.
Although all included studies found reductions in CC
mortality associated with CC screening, some limita-
tions must be mentioned. First, grey literature and non-
English literature were excluded. Second, the NOS used
to assess the risk of bias in the eligible studies was not
specifically created for assessing screening intervention
ab
Fig. 2. (a) Reduction in cervical cancer mortality after attending screening by European region [24] and NOS score. NOS Z Newcastle-
Ottawa scale (i.e. a higher score is a lower risk of bias) [27]; # Uncorrected for self-selection bias; Confidence intervals are shown as error
bars if they were reported in the corresponding study. Fig. 2. (b) Reduction in cervical cancer mortality after being invited for screening in
Northern Europe [24] by NOS score. NOSZ Newcastle-Ottawa scale (i.e. a higher score is a lower risk of bias) [27]; Confidence intervals
are shown as error bars if they were reported in the corresponding study. *Estimation based on Stenkvist et al. [47], women with 2 or more
smears over a ten-year period.
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be present in screening intervention studies, such as the
coexistence of opportunistic screening, that are not
assessed by the NOS. Third, we found no RCTs, which
can be considered to be the gold standard for measuring
the direct effect of an intervention, although also limited
in terms of the ability to generalise from trial data to the
wider population [39]. CC screening was implemented in
most countries before evidence from RCT’s was
collected. However, observational studies with a low
risk of bias do provide important and useful evidence
[40]. Fourth, there was lack of evidence from many
countries within Europe. The lack of evidence from
Southern and Eastern Europe could be because only
11% of these countries have implemented a nationwide
organised screening programme, compared with 88% in
Northern Europe [14,15]. Lastly, the mean publication
year of the included studies was 1997. In recent decades,
the quality of the screening programmes has improved,
with new techniques such as thin layer cytology being
introduced, improving the sensitivity of screening tests
[41] and therefore the effectiveness of the programmes.
However, although the more recent studies might pro-
vide the best estimate of the current CC mortality
reduction, the older studies were of great value because
they were the first to explore the effect of CC screening
on CC mortality, setting the example for further studies.
Women can participate in screening after invitation
from an organised screening programme or on their own
request, that is, opportunistic screening. Organised
screening programmes have many advantages over
opportunistic screening as they tend to achieve higher
participation rates, promote equity of access and are
regularly monitored for quality assurance [11].
Furthermore, organised screening offers additional
benefits by using evidence-based target ages and
screening intervals chosen to reduce harms from
screening, such as overdetection, while optimising the
benefits [6,11].
Newly implemented organised screening programmes
in EU countries should be monitored for their effec-
tiveness, and results should be made available in the
public domain. This will, however, require a major in-
vestment in information systems in many countries,
including linkage with clinical data systems in hospitals
and primary care and with cancer registries [42].
As mentioned previously, the effect of a programme
will depend on the characteristics of the screening test.
Because all of the included studies used cytology as a
primary test, the conclusions cannot be directly applied
to other screening programmes, for instance, using a
primary HPV test. HPV tests achieve higher sensitivity
and specificity than cytology in identifying cervical
intraepithelial neoplasia or cancer in trials [43e45].
Thus, it is reasonable to assume that CC mortalityreduction with programmes using a primary HPV test
will be at least as high as the cytology-based pro-
grammes. In 2017, the Dutch-organised screening pro-
gramme was the first in the world to use the HPV test as
a primary screening test. Monitoring of the outcomes of
this and similar programmes will provide important
information on the effect of HPV screening in practice.
This systematic review focusses on the main goal of
screening: reduction of CC mortality. Yet, despite all its
benefits, screening can also cause harms. Healthy
women who undergo screening can be anxious about the
outcome, overdiagnosed or overtreated [46]. Thus, when
deciding on the optimal screening strategy for a specific
country, one should always weigh the benefits against
the harms, a consideration that was outside the scope of
this systematic review.
Our main conclusion is that even though organised
screening programmes have been running for many
years, there is still relatively little known about the effect
of screening on CC mortality reduction. However,
studies from Finland, Sweden and the United Kingdom
show significant and large effects, confirming the view
that organised CC screening can reduce CC mortality.
These results could be used as a benchmark for other
European countries using similar methods. In the
absence of evidence for a specific programme or coun-
try, modelling could be used to quantify the effects of
individual characteristics of screening programs and the
population on CC mortality reduction for each country.
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Dominika Novak Mlakar
Maja Primic-Zakelj
Martin McKee
Jennifer Priaulxlaou test’/de OR ’uterine cervix cytology’/de OR (((cervix* OR
* OR tumo* OR carcino* OR adenocarcin* OR cytolog*)) OR
OR stain* OR test*)) OR (vagina* NEAR/3 smear*)):ab,ti) AND
(screen* OR ((annual* OR periodic*) NEAR/3 examination*)) OR
ND (mortality/de OR ’cancer mortality’/de OR (mortalit* OR (death
Abstract]/lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim) AND
rope/exp OR (europe* OR Andorra* OR Austria* OR Balkan* OR
Bosnia* OR Herzegovina* OR Bulgaria* OR Croatia* OR Czech*
ia* OR Moldova* OR Montenegr* OR Poland* OR polish* OR
Serbia* OR Slovakia* OR Slovenia* OR Ukraine* OR France* OR
reat-Brit* OR uk OR united-kingdom* OR England* OR Scotland*
eland* OR Italy OR Italian OR Liechtenstein* OR Luxembourg* OR
holland OR Portug* OR San-Marino* OR Scandinavia* OR Nordic*
R finnish OR Iceland* OR Norwa* OR norwegian OR Sweden* OR
zerland* OR swiss):ab,ti,ca,ta,cy,ad) AND (’observational study’/exp
l study’/exp OR ’retrospective study’/exp OR ’prospective study’/exp
rvey’/de OR ’epidemiological data’/de OR ’case control study’/de OR
al study’/de OR ’population research’/de OR ’family study’/de OR
study’/de OR ’comparative study’/de OR ’follow up’/de OR ’clinical
ical trial’/exp OR ’randomization’/exp OR ’intervention study’/de OR
OR ’review’/exp OR ’systematic review’/exp OR (((observation* OR
OR communit*) NEAR/6 (stud* OR data OR research)) OR cohort*
ospectiv* OR population* OR (national* NEAR/3 (stud* OR survey))
OR cases OR match*) NEAR/3 control*) OR (cross NEXT/1 section*)
ulti* NEXT/1 center*) OR ’follow up’ OR followup* OR clinical* OR
nicolaou test"/OR "Vaginal Smears"/OR (((cervix* OR cervical*)
OR carcino* OR adenocarcin* OR cytolog*)) OR Papanicolaou OR
OR (vagina* ADJ3 smear*)).ab,ti.) AND ("Mass Screening"/OR exp
ual* OR periodic*) ADJ3 examination*)) OR (early ADJ3 (diagnos*
r mortality"/OR (mortalit* OR (death ADJ rate*)).ab,ti.) NOT (letter
congresses OR abstracts).pt. AND english.la. AND (exp europe/OR
Balkan* OR Belgi* OR Albania* OR Baltic-State* OR Bosnia* OR
OR Czech* OR Hungar* OR Kosovo* OR Macedonia* OR
OR polish* OR Belarus* OR Romania* OR Russia* OR Serbia* OR
France* OR french OR German* OR Gibraltar* OR Great-Brit* OR
R Scotland* OR Wales* OR welsh OR Greece* OR Ireland* OR Italy
bourg* OR Monaco* OR Netherlands* OR dutch OR holland OR
ia* OR Nordic* OR Denmark* OR danish OR Finland* OR finnish
R Sweden* OR swedish OR Spain* OR spanish OR Switzerland* OR
l study"/OR exp "Cohort Studies"/OR "Health Surveys"/OR
ol Studies"/OR "Cross-Sectional Studies"/OR "multicenter study"/OR
R exp "clinical trials"/OR "Random Allocation"/OR "review"/OR
(continued on next page)
Appendix Table A (continued )
Source Selection code
(((observation* OR epidemiolog*) ADJ6 (stud* OR data OR research)) OR cohort* OR longitudinal* OR
retrospectiv* OR prospectiv* OR population* OR (national* ADJ3 (stud* OR survey)) OR (health* ADJ3
survey*) OR ((case OR cases OR match*) ADJ3 control*) OR (cross ADJ section*) OR correlation* OR
multicenter* OR (multi* ADJ center*) OR "follow up" OR followup* OR clinical* OR trial OR random* OR
review*).ab,ti.)
Cochrane ((((cervix* OR cervical*) NEAR/10 (cancer* OR neoplas* OR tumo* OR carcino* OR adenocarcin* OR
cytolog*)) OR Papanicolaou OR (pap NEXT/1 (smear* OR stain* OR test*)) OR (vagina* NEAR/3
smear*)):ab,ti) AND ((screen* OR ((annual* OR periodic*) NEAR/3 examination*)) OR (early NEAR/3
(diagnos* OR detect*))) AND ((mortalit* OR (death NEXT/1 rate*)):ab,ti) AND ((mortalit* OR (death NEXT/1
rate*)):ab,ti) AND ((europe* OR Andorra* OR Austria* OR Balkan* OR Belgi* OR Albania* OR Baltic-State*
OR Bosnia* OR Herzegovina* OR Bulgaria* OR Croatia* OR Czech* OR Hungar* OR Kosovo* OR
Macedonia* OR Moldova* OR Montenegr* OR Poland* OR polish* OR Belarus* OR Romania* OR Russia*
OR Serbia* OR Slovakia* OR Slovenia* OR Ukraine* OR France* OR french OR German* OR Gibraltar* OR
Great-Brit* OR uk OR united-kingdom* OR England* OR Scotland* OR Wales* OR welsh OR Greece* OR
Ireland* OR Italy OR Italian OR Liechtenstein* OR Luxembourg* OR Monaco* OR Netherlands* OR dutch
OR holland OR Portug* OR San-Marino* OR Scandinavia* OR Nordic* OR Denmark* OR danish OR
Finland* OR finnish OR Iceland* OR Norwa* OR norwegian OR Sweden* OR swedish OR Spain* OR spanish
OR Switzerland* OR swiss))
Web of science TSZ(((((cervix* OR cervical*) NEAR/10 (cancer* OR neoplas* OR tumo* OR carcino* OR adenocarcin* OR
cytolog*)) OR Papanicolaou OR (pap NEAR/1 (smear* OR stain* OR test*)) OR (vagina* NEAR/2 smear*)))
AND ((screen* OR ((annual* OR periodic*) NEAR/2 examination*)) OR (early NEAR/2 (diagnos* OR
detect*))) AND ((mortalit* OR (death NEAR/1 rate*))) AND ((europe* OR Andorra* OR Austria* OR
Balkan* OR Belgi* OR Albania* OR Baltic-State* OR Bosnia* OR Herzegovina* OR Bulgaria* OR Croatia*
OR Czech* OR Hungar* OR Kosovo* OR Macedonia* OR Moldova* OR Montenegr* OR Poland* OR
polish* OR Belarus* OR Romania* OR Russia* OR Serbia* OR Slovakia* OR Slovenia* OR Ukraine* OR
France* OR french OR German* OR Gibraltar* OR Great-Brit* OR uk OR united-kingdom* OR England* OR
Scotland* OR Wales* OR welsh OR Greece* OR Ireland* OR Italy OR Italian OR Liechtenstein* OR
Luxembourg* OR Monaco* OR Netherlands* OR dutch OR holland OR Portug* OR San-Marino* OR
Scandinavia* OR Nordic* OR Denmark* OR danish OR Finland* OR finnish OR Iceland* OR Norwa* OR
norwegian OR Sweden* OR swedish OR Spain* OR spanish OR Switzerland* OR swiss)) AND (((observation*
OR epidemiolog* OR famil* OR comparativ* OR communit*) NEAR/5 (stud* OR data OR research)) OR
cohort* OR longitudinal* OR retrospectiv* OR prospectiv* OR population* OR (national* NEAR/2 (stud* OR
survey)) OR (health* NEAR/2 survey*) OR ((case OR cases OR match*) NEAR/2 control*) OR (cross NEAR/1
section*) OR correlation* OR multicenter* OR (multi* NEAR/1 center*) OR"follow up" OR followup* OR
clinical* OR trial OR random* OR review*)) AND DTZ(article) AND laZ(english)
PubMed publisher ("Uterine Cervical Neoplasms"[mh] OR "Papanicolaou test"[mh] OR "Vaginal Smears"[mh] OR (((cervix*[tiab]
OR cervical*[tiab]) AND (cancer*[tiab] OR neoplas*[tiab] OR tumo*[tiab] OR carcino*[tiab] OR adenocarcin*
[tiab] OR cytolog*[tiab])) OR Papanicolaou OR pap smear*[tiab] OR pap stain*[tiab] OR pap test*[tiab] OR
vaginal smear*[tiab])) AND ("Mass Screening"[mh] OR "Early Diagnosis"[mh] OR (screen*[tiab] OR ((annual*
[tiab] OR periodic*[tiab]) AND examination*[tiab])) OR (early AND (diagnos*[tiab] OR detect*[tiab]))) AND
(mortality[mh] OR "cancer mortality"[mh] OR (mortalit*[tiab] OR (death rate*[tiab]))) NOT (letter[pt] OR news
[pt] OR comment[pt] OR editorial[pt] OR congresses[pt] OR abstracts[pt]) AND english[la] AND english[la]
AND (europe[mh] OR (europe* OR Andorra* OR Austria* OR Balkan* OR Belgi* OR Albania* OR Baltic-
State* OR Bosnia* OR Herzegovina* OR Bulgaria* OR Croatia* OR Czech* OR Hungar* OR Kosovo* OR
Macedonia* OR Moldova* OR Montenegr* OR Poland* OR polish* OR Belarus* OR Romania* OR Russia*
OR Serbia* OR Slovakia* OR Slovenia* OR Ukraine* OR France* OR french OR German* OR Gibraltar* OR
Great-Brit* OR uk OR united-kingdom* OR England* OR Scotland* OR Wales* OR welsh OR Greece* OR
Ireland* OR Italy OR Italian OR Liechtenstein* OR Luxembourg* OR Monaco* OR Netherlands* OR dutch
OR holland OR Portug* OR San-Marino* OR Scandinavia* OR Nordic* OR Denmark* OR danish OR
Finland* OR finnish OR Iceland* OR Norwa* OR norwegian OR Sweden* OR swedish OR Spain* OR spanish
OR Switzerland* OR swiss)) AND ("observational study"[pt] OR "Cohort Studies"[mh] OR "Health
Surveys"[mh] OR "Epidemiologic Studies"[mh] OR "Case-Control Studies"[mh] OR "Cross-Sectional
Studies"[mh] OR "multicenter study"[pt] OR "comparative study"[pt] OR "clinical study"[pt] OR "clinical
trials"[pt] OR "Random Allocation"[mh] OR "review"[pt] OR (((observation*[tiab] OR epidemiolog*[tiab]) AND
(stud*[tiab] OR data OR research)) OR cohort*[tiab] OR longitudinal*[tiab] OR retrospectiv*[tiab] OR
prospectiv*[tiab] OR population*[tiab] OR (national*[tiab] AND (stud*[tiab] OR survey)) OR (health*[tiab]
AND survey*[tiab]) OR ((case OR cases OR match*[tiab]) AND control*[tiab]) OR (cross section*[tiab]) OR
correlation*[tiab] OR multicenter*[tiab] OR (multi center*[tiab]) OR "follow up" OR followup*[tiab] OR
clinical*[tiab] OR trial OR random*[tiab] OR review*[tiab])) AND publisher[sb]
Google Scholar "cervixjcervical cancerjneoplasmjtumorjcarcinomajadenocarcinomajcytology"j"pap smearjstainjtest"j"vaginal
smear" screening mortalityj"death rate" europe
cohortjlongitudinaljprospectivejretrospectivejtrialjepidemiologicaljepidemiologic
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Appendix Table B
Characteristics of excluded studies.
Study Reason for exclusion Study Reason for exclusion
Van der Aa M, 1993 The study did not provide absolute numbers
of events and participants or a relative risk.
Kostova P, 2010 No group sizes reported and no relative
risk.
Aareleid T, 1993 Rates before and after screening
implementation. Causal relation between
screening and mortality reduction not
tested.
Kova´cs A, 2008 Study provides no mortality or incidence
data
Adami H, 1994 The study did not provide absolute numbers
of events or a relative risk.
Laara E, 1987 The study did not provide absolute numbers
of events and participants or a relative risk.
D’Alo` D, 2010 Causal relation between screening and
mortality reduction not tested.
Lo¨nnberg S, 2012 No mortality outcomes, only incidence
Andrae B, 2008 No mortality outcomes, only incidence Louhivuori K, 1991 Causal relation between screening and
mortality reduction not tested.
Anttila A, 1999 Control group receives screening. Ma´jek O, 2016 Follow-up <5 years.
Anttila A, 2007 Provides an overview of other studies. Minelli L, 2007 The study did not provide absolute numbers
of events and participants or a relative risk.
Anttila A, 2011 Control group receives screening. Murphy M, 1987 The study did not provide absolute numbers
of events and participants or a relative risk.
Apostol I, 2010 No baseline measurement. Nieminen P, 1995 No number of events reported and no
relative risk.
Arbyn M, 2012 Provides an overview of other studies. Nieminen P, 1999 No mortality outcomes, only incidence
Bojar I, 2012 Presented results are on absolute reductions. Nowakowski A, 2015 No number of events reported and no
relative risk.
Castillo M, 2018 Full article not available in English. Nygard J, 2002 No absolute number of events. Control
group receives screening.
Comber H, 2004 Causal relation between screening and
mortality reduction not tested.
Parazzini F, 1990 No mortality outcomes, only incidence
Cossu A, 2014 Causal relation between screening and
mortality reduction not tested.
Peto J, 2004 No population size, estimation of deaths
without screening based on past. Causal
relation between screening and mortality
reduction not tested.
Crocetti E, 2007 No mortality outcomes, only incidence Petterson F, 1995 No number of events reported and no
relative risk.
Day N, Provides an overview of other studies. Quinn M, 1999 No number of events reported and no
relative risk.
Ferraroni M, 1989 No mortality or incidence data provided. Ronco G, 2005 No mortality outcomes, only incidence
Gad C, 1976 Causal relation between screening and
mortality reduction not tested.
Sasieni P, 2009 No mortality outcomes, only incidence
Habbema D, 2012 Control group receives screening. De Schryver A, 1989 Causal relation between screening and
mortality reduction not tested. No relative
risk.
Hakama M, 1976 Intervention group was after first negative
smear.
Serraino D, 2015 No mortality outcomes, only incidence
Hakama M, 1985 Provides an overview of other studies. No
group sizes reported and same data as
Hakulinen 1985.
Sigurdsson K, 1989 Causal relation between screening and
mortality reduction not tested. No relative
risk.
Hakulinen T, 1985 Provides an overview of other studies. No
group sizes reported and no relative risk.
Sigurdsson K, 1993 Causal relation between screening and
mortality reduction not tested. No relative
risk.
Herbert A, 1998 Trend analysis. Causal relation between
screening and mortality reduction not
tested.
Sigurdsson K, 1999 Causal relation between screening and
mortality reduction not tested. No relative
risk.
Herbert A, 2000 No group sizes reported and no relative
risk.
Sigurdsson K, 2006 Causal relation between screening and
mortality reduction not tested. No relative
risk.
Johannesson G, 1982 Presented results do not take screening
history into account. No relative risk.
Simonella L, 2013 No number of cases reported. No control
group.
Karxzmarek-Borowska
B, 2013
Full article not available in English. Timonen S, 1974 Letter, No number of study groups or a
relative risk.
Kinney W, 2003 Study not performed in Europe (U.S.A.) Timonen S, 1974 No number of study groups or a relative
risk.
Kok I, 2011 Causal relation between screening and
mortality reduction not tested.
Timonen S, 1977 The study did not provide absolute numbers
of events and participants.
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Appendix Table C.1
Risk of bias in Case-control studies according to NewcastleeOttawa Scale.
Selection Comparability Exposure
Study Case definition Representativeness of
the cases
Control selection Control definition Study controls for
age
Any additional
factors
Ascertainment Same method
for case and
control
Non-Response rate Final result
Landy
R, 2016
Yes, but no actual
deaths were counted,
calculated number of
deaths based on
survival data were used.
Consecutive series of
cases. All women who
had cervical cancer
between April 2007 and
March 2013. (*)
Community
controls. “All
women registered
with an NHS GP
who did not have
cervical cancer at
the time of
diagnosis were
eligible as a
control.” (*)
No history of
disease. “All
women registered
with an NHS GP
who did not have
cervical cancer at
the time of
diagnosis were
eligible as a
control.” (*)
Controls were
matched for age. (*)
Controls were
matched for area of
residence. (*)
Secure record.
Screening data were
abstracted from
routinely recorded
cervical cytology
records held on the
Cervical Screening
call/recall system
which include all
NHS smears taken
in the UK. (*)
Yes. (*) Same rate for both
groups.
Records include all
NHS smears taken
in the UK. (*)
8/9
Lo¨nnberg
S, 2013
Record linkage with the
cancer register. Cancer
register has 99.5%
histologically verified
cases [29]. (*)
Consecutive series of
cases. All registered
cervical cancer deaths
from the years 2000
e2009. (*)
Community
controls, drawn
from the
population register.
(*)
No history of
disease. “Only
women alive and
not diagnosed with
cervical cancer at
the time of
diagnosis of the
case were eligible as
controls.” (*)
Cases and controls
were matched for
birth year and
month. (*)
Study corrected for
self-selection bias.
(*)
Secure record.
Study objects were
linked to the
screening register
database. (*)
Yes. (*) Same rate for both
groups. Thirty-nine
cases excluded for
other reasons. (*)
9/9
Macgregor
E, 1994
Yes, the records of the
cases were obtained
from hospital records
and the cytopathology
database. (*)
Not stated. No description. No history of
disease. Controls
have had a negative
smear test result at
the date of
presentation of the
case. (*)
Controls were
matched for age. (*)
No. Secure record.
Screening history
was assessed using
the cytopathology
database. (*)
No statement. Non-respondents
described.
4/9
(*) The presence of this symbol means the study fitted the selected criteria and it was accounted in the final result. NHS, National Health Service; GP, general practitioner.
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Appendix Table C.2
Risk of bias in cohort studies according to Newcastle-Ottawa Scale.
Selection Comparability Outcome
Study Representativeness of
the exposed cohort
Selection of the non-
exposed
Ascertainment of
exposure
Absence of
interest
outcome at
start of study
Study controls for
age
Any additional
factors
Assessment of outcome Follow-up
Length (>8
years)
Adequacy of
follow-up
Final
result
Berget A,
1979
Truly representative of
the average Danish
female population
between 30 and 49 years
old as all were invited
for screening. (*)
Drawn from the same
community as the
exposed cohort. Not
attending women. (*)
Invitation lists and
meeting lists were used
to measure invitation
and attendance. (*)
Yes. Women
with prior
cervical lesion
or
hysterectomy
were excluded.
(*)
No. Quote: “The
size of the study
population does not
allow correction for
this.
No. Record linkage using
death certificates and
data from the Danish
Cancer Registry. (*)
No. 6e8 years. Yes. Only 0.64%
were not identified
and excluded.
Emigrated women
were followed and/
well described. (*)
6/9
Bergstro¨m
S, 1999
Truly representative of
the average Swedish
female population
between 30 and 49 years
old as all were invited
for screening. (*)
Drawn from the same
community as the
exposed cohort. Same
population in the years
before implementation
of screening. (*)
Amount of smears
reported, but the
method of
ascertainment is not
described.
No. Standardised for
age to the Swedish
census population
in 1970. (*)
Study corrected for
period and cohort.
(*)
Record linkage using
the Swedish Cancer
Register and the
Swedish Cause of
Death Register at
Statistics Sweden. (*)
Yes. 26e36
years. (*)
No statement. 6/9
Dugue´ P,
2014
Truly representative of
the average Danish
population between 23
and 51 years old, as all
had the possibility to
participate in two
rounds of screening. (*)
Drawn from the same
community as the
exposed cohort. Not
attending women. (*)
Secure record. Data on
samples were retrieved
from the Danish
Pathology Data Bank,
the National Health
Service Register and the
National Patient
Register. (*)
No. Yes. (*) No. Record linkage between
the Danish Civil
Registration System
and the Danish Cause
of Death Register using
personal ID numbers.
(*)
Yes. 13 years.
(*)
Small number lost.
Unlikely to
introduce bias. (*)
7/9
Ebeling K,
1986
Somewhat
representative of the
average Berlin women
between 20 and 64 years
old. (*)
Drawn from the same
community as the
exposed cohort. Not
attending women. (*)
No description of
method. Screening
histories of all patients
with cervical cancer
were carefully
monitored.
No. No correction for
age.
No. Smears were re-
examined and records
of gynaecologists and
gynaecological
hospitals were checked.
(*)
Yes. 10 years.
(*)
No statement. 4/9
Lynge E,
1989
Somewhat
representative of the
average Danish female
population between 30
and 59 years old as
some counties were
excluded. (*)
Drawn from a different
source. Different areas,
with low smear-taking
activity
No description of
method. Authors only
mention that data are
available.
No. The study corrected
for 6 5-year age
groups using a
Poisson model. (*)
The study corrected
for 4 5-year
calender periods
and 19 counties. (*)
Record linkage with
death certificates and
the Danish Cancer
Registry. (*)
Yes w15 years.
(*)
No statement. 5/9
Magnus K,
1987
Truly representative of
the average female
population in the
county of Ostfold
between 25 and 59 years
old as all were invited
for screening. (*)
Drawn from a different
source. Female
population of
neighbouring counties.
Rates are only used
from 1963 to 1967.
Secure record.
Screening history by
national identification
number. (*)
No. No. No. Record linkage between
the Cancer Registry and
the Central Bureau of
Statistics. (*)
Yes. 24 years.
(*)
No statement. 4/9
Ma¨hlck C,
1994
Truly representative of
the average Swedish
female population
between 30 and 49 years
old as all were invited
for screening. (*)
Drawn from the same
community as the
exposed cohort. Same
population in the years
before implementation
of screening. (*)
No description. No. Yes, with the
population of
Sweden 1970 as a
reference. (*)
Study controls for
period and county.
(*)
Record linkage between
the Population Register
and the Cause of Death
Register at the Swedish
Central Bureau of
Statistics. (*)
Yes. 22 years.
(*)
No statement. 6/9
(*) The presence of this symbol means the study fitted the selected criteria and it was accounted in the final result.
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Appendix Table D
Conflict of interest and/or statements of all included studies.
Study Conflict of interest and/or funding statement
Berget A, 1979 No statement.
Bergstro¨m S, 1999 No statement.
Dugue´ P, 2014 Pierre-Antoine Dugue´ declares no potential conflict of interest. Elsebeth Lynge and Matejka Rebolj are currently
undertaking a comparative study of new-generation HPV tests, involving collaboration with Roche Diagnostics,
Genomica, Qiagen and Genprobe. Elsebeth Lynge has served as unpaid scientific advisor to Genprobe and Norchip.
Matejka Rebolj’s employer received honoraria for lectures from Qiagen on her behalf. Concerning the present paper,
there has been no collaboration with, or support from any of the companies. Grant sponsor: University of
Copenhagen, Danish Strategic Research Council.
Ebeling K, 1986 No statement.
Landy R, 2016 The authors declare no conflict of interest. This work was supported by Cancer Research UK (A16892 to P.S.).
Lo¨nnberg S, 2013 Grant sponsors: Finnish Cancer Organisations; European Union Seventh Framework Programme contract
EUROCOURSE-Europe against Cancer: Optimisation of the Use of Registries for Scientific Excellence in research.
Co-funding was provided by the European Union Public Health Programme (Project no. 2006322, European
Cooperation on Development and Implementation of Cancer Screening and Prevention Guidelines [ECCG]).
Lynge E, 1989 The costs of publication of this article were defrayed in part by payment of page charges. This article must therefore
be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Macgregor E, 1994 No statement.
Magnus K, 1987 No statement.
Ma¨hlck C, 1994 This investigation was supported by Lions’ Research Foundation, University of Umea and by Swedish Cancer
Society (RmC), project no. 1759-B89-03XB.
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